Details
Originalsprache | Englisch |
---|---|
Seiten (von - bis) | 4731-4742 |
Seitenumfang | 12 |
Fachzeitschrift | Vaccine |
Jahrgang | 41 |
Ausgabenummer | 32 |
Frühes Online-Datum | 21 Juni 2023 |
Publikationsstatus | Veröffentlicht - 19 Juli 2023 |
Abstract
A promising new vaccine platform is based on the Orf virus, a viral vector of the genus Parapoxvirus, which is currently being tested in phase I clinical trials. The application as a vaccine platform mandates a well-characterised, robust, and efficient production process. To identify critical process parameters in the production process affecting the virus’ infectivity, the Orf virus was subjected to forced degradation studies, including thermal, pH, chemical, and mechanical stress conditions. The tests indicated a robust virus infectivity within a pH range of 5–7.4 and in the presence of the tested buffering substances (TRIS, HEPES, PBS). The ionic strength up to 0.5 M had no influence on the Orf virus’ infectivity stability for NaCl and MgCl2, while NH4Cl destabilized significantly. Furthermore, short-term thermal stress of 2 d up to 37 °C and repeated freeze-thaw cycles (20 cycles) did not affect the virus’ infectivity. The addition of recombinant human serum albumin was found to reduce virus inactivation. Last, the Orf virus showed a low shear sensitivity induced by peristaltic pumps and mixing, but was sensitive to ultrasonication. The isoelectric point of the applied Orf virus genotype D1707-V was determined at pH 3.5. The broad picture of the Orf virus’ infectivity stability against environmental parameters is an important contribution for the identification of critical process parameters for the production process, and supports the development of a stable pharmaceutical formulation. The work is specifically relevant for enveloped (large DNA) viruses, like the Orf virus and like most vectored vaccine approaches.
ASJC Scopus Sachgebiete
- Biochemie, Genetik und Molekularbiologie (insg.)
- Molekularmedizin
- Immunologie und Mikrobiologie (insg.)
- Veterinärmedizin (insg.)
- Medizin (insg.)
- Öffentliche Gesundheit, Umwelt- und Arbeitsmedizin
- Medizin (insg.)
- Infektionskrankheiten
Ziele für nachhaltige Entwicklung
Zitieren
- Standard
- Harvard
- Apa
- Vancouver
- BibTex
- RIS
in: Vaccine, Jahrgang 41, Nr. 32, 19.07.2023, S. 4731-4742.
Publikation: Beitrag in Fachzeitschrift › Artikel › Forschung › Peer-Review
}
TY - JOUR
T1 - Stability studies for the identification of critical process parameters for a pharmaceutical production of the Orf virus
AU - Eilts, Friederike
AU - Labisch, Jennifer J.
AU - Orbay, Sabri
AU - Harsy, Yasmina M.J.
AU - Steger, Marleen
AU - Pagallies, Felix
AU - Amann, Ralf
AU - Pflanz, Karl
AU - Wolff, Michael W.
N1 - Funding Information: The authors would like to thank Philip Wiese for the support with the infectivity analytics as well as Keven Lothert and Catherine Meckel-Oschmann for the proofreading of the manuscript. We kindly thank Albumedix Ltd. for the provided rHSA, Recombumin Prime, used in this study. The graphical abstract was created with biorender.com. This work was financially supported by the Heinrich-Böll-Foundation with a doctoral scholarship to F. Eilts. Additionally, an EXIST-Forschungstransfer grant (03EFKBW171) of the German Federal Ministry for Economic Affairs and Energy was granted and the project was co-funded by the European Regional Development Fund as part of the Union's response to the COVID-19 pandemic (IGJ-ERDF-Program Hesse - React EU 20008790). The presented manuscript is part of F. Eilts' dissertation at the Graduate Centre for Engineering Sciences under the aegis of the Justus Liebig University Giessen, Germany, in cooperation with the University of Applied Sciences Mittelhessen, Giessen, Germany.
PY - 2023/7/19
Y1 - 2023/7/19
N2 - A promising new vaccine platform is based on the Orf virus, a viral vector of the genus Parapoxvirus, which is currently being tested in phase I clinical trials. The application as a vaccine platform mandates a well-characterised, robust, and efficient production process. To identify critical process parameters in the production process affecting the virus’ infectivity, the Orf virus was subjected to forced degradation studies, including thermal, pH, chemical, and mechanical stress conditions. The tests indicated a robust virus infectivity within a pH range of 5–7.4 and in the presence of the tested buffering substances (TRIS, HEPES, PBS). The ionic strength up to 0.5 M had no influence on the Orf virus’ infectivity stability for NaCl and MgCl2, while NH4Cl destabilized significantly. Furthermore, short-term thermal stress of 2 d up to 37 °C and repeated freeze-thaw cycles (20 cycles) did not affect the virus’ infectivity. The addition of recombinant human serum albumin was found to reduce virus inactivation. Last, the Orf virus showed a low shear sensitivity induced by peristaltic pumps and mixing, but was sensitive to ultrasonication. The isoelectric point of the applied Orf virus genotype D1707-V was determined at pH 3.5. The broad picture of the Orf virus’ infectivity stability against environmental parameters is an important contribution for the identification of critical process parameters for the production process, and supports the development of a stable pharmaceutical formulation. The work is specifically relevant for enveloped (large DNA) viruses, like the Orf virus and like most vectored vaccine approaches.
AB - A promising new vaccine platform is based on the Orf virus, a viral vector of the genus Parapoxvirus, which is currently being tested in phase I clinical trials. The application as a vaccine platform mandates a well-characterised, robust, and efficient production process. To identify critical process parameters in the production process affecting the virus’ infectivity, the Orf virus was subjected to forced degradation studies, including thermal, pH, chemical, and mechanical stress conditions. The tests indicated a robust virus infectivity within a pH range of 5–7.4 and in the presence of the tested buffering substances (TRIS, HEPES, PBS). The ionic strength up to 0.5 M had no influence on the Orf virus’ infectivity stability for NaCl and MgCl2, while NH4Cl destabilized significantly. Furthermore, short-term thermal stress of 2 d up to 37 °C and repeated freeze-thaw cycles (20 cycles) did not affect the virus’ infectivity. The addition of recombinant human serum albumin was found to reduce virus inactivation. Last, the Orf virus showed a low shear sensitivity induced by peristaltic pumps and mixing, but was sensitive to ultrasonication. The isoelectric point of the applied Orf virus genotype D1707-V was determined at pH 3.5. The broad picture of the Orf virus’ infectivity stability against environmental parameters is an important contribution for the identification of critical process parameters for the production process, and supports the development of a stable pharmaceutical formulation. The work is specifically relevant for enveloped (large DNA) viruses, like the Orf virus and like most vectored vaccine approaches.
KW - Downstream processing
KW - Forced degradation studies
KW - Formulation
KW - Parapox Orf virus
KW - Viral vector vaccine
UR - http://www.scopus.com/inward/record.url?scp=85162863385&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2023.06.047
DO - 10.1016/j.vaccine.2023.06.047
M3 - Article
C2 - 37353451
AN - SCOPUS:85162863385
VL - 41
SP - 4731
EP - 4742
JO - Vaccine
JF - Vaccine
SN - 0264-410X
IS - 32
ER -